Abstracts tagged "gout"

Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
Abstract Number: 0177 • ACR Convergence 2021
Dual-Energy Computed Tomography Three Material Decomposition Improves the Sensitivity of Gout Detection
Justin Tse¹, Douglas Kondro², Yves Pauchard³, Andrea Veljkovic⁴, Viviane Frasson⁵, David Holdsworth⁶, Sarah Manske⁷, Paul MacMullan⁸ and Peter Salat⁷, ¹UNIVERSITY OF CALGARY, Calgary, AB, Canada, ²STEMCELL Technologies, Cambridge, United Kingdom, ³Department of Electrical and Software Engineering, Schulich School of Engineering, Calgary, AB, Canada, ⁴University of British Columbia, Department of Orthopaedics, Vancouver, BC, Canada, ⁵University of Calgary, Human Performance Lab, Calgary, AB, Canada, ⁶University of Western Ontario, Department of Surgery, London, ON, Canada, ⁷University of Calgary, Department of Radiology, Calgary, AB, Canada, ⁸University of Calgary, Department of Rheumatology, Calgary, AB, Canada
Background/Purpose: Gout, a curable musculoskeletal disease, is characterized by the deposition and accumulation of monosodium urate (MSU) crystals within affected joints. Dual-energy computed tomography (DECT),…
Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Jasvinder Singh¹, Kenneth Saag¹, Joshua Baker², Amy Joseph³, Seth Eisen⁴ and Terence Shaneyfelt¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Washington University / St. Louis VA, St Louis, MO, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…
Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Kazuki Yoshida¹, Robert J. Glynn¹, Hyon K. Choi², Brendan M. Everett¹, Yi Li³, Jean G. MacFadyen¹, Paul M. Ridker¹ and DH Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…
Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
James O'Dell¹, Tuhina Neogi², Michael Pillinger³, Paul Palevsky⁴, Jeff Newcomb¹, Mary Brophy⁵, Hongsheng Wu⁵, Annie Davis-Karim⁶, Ryan Ferguson⁵, David Pittman⁶, Robert Terkeltaub⁷, Amy Cannella¹, Bryant England¹, Lindsay Helget¹, Ted Mikuls¹ and Tomas Taylor⁸, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³New York University Grossman School of Medicine, New York,, NY, ⁴Pittsburgh University, Pittsburgh, PA, ⁵Boston VA, Boston, MA, ⁶Albuquerque VA, Albuquerque, NM, ⁷VA/UCSD, San Diego, CA, ⁸White River Junction VA, White River Junction, VT
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
Abstract Number: 0467 • ACR Convergence 2021
Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)
Michael Toprover¹, Michael Mechlin¹, Anastasia Slobodnick¹, Virginia Pike¹, Cheongeun Oh¹, Claudine Davis¹, Theodore Fields², Fabio Becce³ and Michael Pillinger⁴, ¹NYU Langone Health, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Axial gout involvement was first reported in 1950 (1). Over 100 cases have subsequently been published. Reported cases have presented as acute back pain,…
Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Anushree Tiku¹, Neil Boudville², Fiona Brown³, Alan Cass⁴, Phiilip Clarke⁵, Richard Day⁶, Janak de Zoysa⁷, Bettina Douglas⁸, Randall Faull⁹, David Harris¹⁰, Carmel Hawley¹¹, Graham Jones⁶, John Kanellis³, Elaine Pascoe¹¹, Suetonia Palmer¹², Vlado Perkovic¹³, Gopala Rangan¹⁰, Donna Reidlinger¹¹, Laura Robison¹¹, Robert Walker¹⁴, Giles Walters¹⁵, David Johnson¹¹, Sunil Badve¹³ and Nicola Dalbeth⁷, ¹The George Institute of Australia, Sydney, Australia, ²University of Western Australia, Perth, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies School of Health Research, Darwin, Australia, ⁵University of Oxford, Oxford, United Kingdom, ⁶University of New South Wales, Sydney, Australia, ⁷University of Auckland, Auckland, New Zealand, ⁸Princess Alexandra Hospital, Brisbane, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰University of Sydney, Sydney, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²University of Otago, Christchurch, New Zealand, ¹³The George Institute for Global Health, Sydney, Australia, ¹⁴University of Otago, Dunedin, New Zealand, ¹⁵The Canberra Hospital, Canberra, Australia
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…
Abstract Number: 1567 • ACR Convergence 2021
Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
Luigi Brunetti¹, Lujing Wang², Andrew Wassef², Anita Brinker³, Brian T Buckley⁴, Peter Lipsky⁵, Ah-Ng Kong² and Naomi Schlesinger⁶, ¹Rutgers The State University of New Jersey, Piscataway, NJ, ²Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, ³Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey,, Piscataway, NJ, ⁴Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, ⁵AMPEL BioSolutions, Charlottesville, VA, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Tart cherries (TC) contain high levels of anthocyanins that exert potent antioxidant and anti-inflammatory effects. Approximately 50% of gout patients report using TC to…
Abstract Number: 0578 • ACR Convergence 2021
Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic (insulin resistance) syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate (SU) levels in physiologic studies1 and…
Abstract Number: 0676 • ACR Convergence 2021
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Lesley Jackson¹, Narender Annapureddy², Kenneth Saag¹, James Booth³, Giovanna Rosas¹, Jeffrey Foster¹, Amy Mudano¹, Dongmei Sun⁴, John Osborne¹, Tim Bongartz⁵, Erik Hess⁵, Colleen Lawrence⁶, Leah Dunkel⁶ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁶Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting…
Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
zancong shen¹, Elizabeth Polvent², vijay hingorani³, Rongzi Yan⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc., San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Vanguard Healthsciences, Inc., San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
Abstract Number: 0660 • ACR Convergence 2021
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Kazuki Yoshida, Tianrun Cai, Lily G. Bessette, Erin Kim, Su Been Lee, Luke E. Zabotka, Alec Sun, Jun Liu, DH Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recurrent gout flares are the most crucial outcome in studies of gout treatment. However, gout flares is challenging to identify in a large population…
Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…
Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Christopher Podgorski¹, Paula Skarda² and Elie Gertner³, ¹Department of Medicine, University of Minnesota Medical School, Saint Paul, MN, ²Department of Medicine, Regions Hospital, University of Minnesota Medical School, Saint Paul, MN, ³Section of Rheumatology, Regions Hospital and Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.